Evidence map›Paper›PMID 35974226›Full record

SynthesisClinical rheumatology2022

Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis.

Yasmin Khader, Azizullah Beran, Sami Ghazaleh, Wade Lee-Smith, Nezam Altorok

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Observational
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Rheumatoid Arthritis: Biomarkers and the Latest Breakthroughs.International journal of molecular sciences · 2025
    Review
  14. Article
  15. Observational
  16. Review
  17. Observational
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yasmin KhaderDepartment of Internal Medicine, University of Toledo, 2100 West Central Ave, Toledo, OH, 43606, USA. Yasmin.Khader@Utoledo.EduYasmin.Khader.ORCID http://orcid.org/0000-0001-5711-8753
Azizullah BeranDepartment of Internal Medicine, University of Toledo, 2100 West Central Ave, Toledo, OH, 43606, USA.
Sami GhazalehDepartment of Internal Medicine, University of Toledo, 2100 West Central Ave, Toledo, OH, 43606, USA.
Wade Lee-SmithUniversity of Toledo Libraries, University of Toledo, Toledo, OH, USA.
Nezam AltorokDepartment of Rheumatology, University of Toledo, Toledo, OH, USA.
University of Toledo · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biologics have emerged as an effective treatment of rheumatoid arthritis (RA). However, there is a significant proportion of patients who fail to respond to biologics. Identifying the predictors that affect the response to biologics remains challenging. A comprehensive literature search of PubMed, Embase, and Web of Science databases was conducted through May 1, 2022. We included all studies that used a multivariate model to assess for the predictors of remission in RA patients treated with biologics. We calculated pooled odds ratios (OR) with 95% confidence intervals (CI) for risk factors reported in ≥ 3 studies using a random-effects model. A total of 16,934 patients with RA who were treated with biologics were included in twenty-one studies. Our study showed that old age (OR 0.98 (0.97, 0.99), P < 0.00001), female gender (OR 0.66 (0.56, 0.77), P < 0.00001), smoking history (OR 0.86 (0.75, 0.99), P 0.04), obesity (OR 0.95 (0.91, 0.99), P 0.02), poor functional status (OR 0.62 (0.48, 1.27), P < 0.00001), high disease activity (OR 0.90 (0.85, 0.96), P 0.0005), and elevated erythrocyte sedimentation rate (OR 0.99 (0.98, 1.00), P 0.009) were poor predictors of remission. On the other hand, positive anti-citrullinated protein antibodies (OR 2.52 (1.53, 4.12), P 0.0003) was associated with high remission rate. Old age, female gender, obesity, smoking history, poor functional status, high disease activity, and elevated ESR at the time of diagnosis have been associated with poor response to biologics. Our findings could help establish a risk stratification model for predicting the remission rate in RA patients receiving biologics.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidBiological ProductsAnti-Citrullinated Protein AntibodiesFemaleHumansObesityRemission InductionAnti-Citrullinated Protein AntibodiesAntirheumatic AgentsBiological ProductsBiologic therapyDisease activity scoreRemissionRheumatoid arthritis

Identifiers

PMID35974226
PMCPMC9652218
OpenAlexW4292014168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.